{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:52:52Z","timestamp":1790707972171,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ajps.2021.06.001","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T01:22:08Z","timestamp":1625102528000},"page":"35-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy"],"prefix":"10.1016","volume":"17","author":[{"given":"Haijie","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajps.2021.06.001_bib0001","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ajps.2021.06.001_bib0002","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1021\/mp300370t","article-title":"Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications","volume":"10","author":"Moysan","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ajps.2021.06.001_bib0003","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajps.2021.06.001_bib0004","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/17425247.2011.632630","article-title":"Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity","volume":"8","author":"Celia","year":"2011","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.ajps.2021.06.001_bib0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejps.2016.08.021","article-title":"Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine","volume":"93","author":"Dubey","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijpharm.2014.05.005","article-title":"Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate","volume":"470","author":"Khare","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ajps.2021.06.001_bib0007","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ajps.2021.06.001_bib0008","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.addr.2016.06.015","article-title":"Peptide-drug conjugates as effective prodrug strategies for targeted delivery","volume":"110-111","author":"Wang","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0009","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/bc700333s","article-title":"Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers","volume":"19","author":"Zhao","year":"2008","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ajps.2021.06.001_bib0010","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1039\/C4TB01984A","article-title":"Doxorubicin conjugated phospholipid prodrugs as smart nanomedicine platforms for cancer therapy","volume":"3","author":"Wang","year":"2015","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.ajps.2021.06.001_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2010.12.005","article-title":"Prodrug-based intracellular delivery of anticancer agents","volume":"63","author":"Bildstein","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0012","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0013","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jconrel.2020.04.039","article-title":"Application of star poly(ethylene glycol) derivatives in drug delivery and controlled release","volume":"323","author":"Zhao","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0014","doi-asserted-by":"crossref","first-page":"9340","DOI":"10.1016\/j.biomaterials.2010.08.010","article-title":"Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer","volume":"31","author":"Vandana","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ajps.2021.06.001_bib0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jconrel.2008.02.002","article-title":"Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid","volume":"127","author":"Pasut","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0016","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1039\/C9TB02259G","article-title":"A tumor-targeted, intracellular activatable and theranostic nanodiamond drug platform for strongly enhanced in vivo antitumor therapy","volume":"8","author":"Du","year":"2020","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.ajps.2021.06.001_bib0017","doi-asserted-by":"crossref","first-page":"11657","DOI":"10.1021\/ja405372k","article-title":"Folate-based near-infrared fluorescent theranostic gemcitabine delivery","volume":"135","author":"Yang","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ajps.2021.06.001_bib0018","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.addr.2009.09.005","article-title":"Squalene: a natural triterpene for use in disease management and therapy","volume":"61","author":"Reddy","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0019","doi-asserted-by":"crossref","first-page":"15678","DOI":"10.1038\/ncomms15678","article-title":"Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery","volume":"8","author":"Sobot","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajps.2021.06.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147570","article-title":"Squalene Inhibits ATM-dependent signaling in \u03b3IR-induced DNA damage response through induction of wip1 phosphatase","volume":"11","author":"Tatewaki","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ajps.2021.06.001_bib0021","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.nano.2011.02.012","article-title":"Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer","volume":"7","author":"R\u00e9jiba","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ajps.2021.06.001_bib0022","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11051-007-9322-7","article-title":"Oral absorption and tissue distribution of a new squalenoyl anticancer nanomedicine","volume":"10","author":"Harivardhan Reddy","year":"2008","journal-title":"J Nanopartical Res"},{"key":"10.1016\/j.ajps.2021.06.001_bib0023","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/CAD.0b013e3283126585","article-title":"Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms","volume":"19","author":"Reddy","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ajps.2021.06.001_bib0024","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.4155\/fmc-2017-0095","article-title":"Fluorinated nucleosides as an important class of anticancer and antiviral agents","volume":"9","author":"Cavaliere","year":"2017","journal-title":"Future Med Chem"},{"key":"10.1016\/j.ajps.2021.06.001_bib0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2141.2008.07467.x","article-title":"CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines","volume":"144","author":"Galmarini","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ajps.2021.06.001_bib0026","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1007\/s10637-011-9756-8","article-title":"Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126","volume":"30","author":"Adema","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ajps.2021.06.001_bib0027","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbalip.2016.08.001","article-title":"Known unknowns of cardiolipin signaling: the best is yet to come","volume":"1862","author":"Maguire","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.ajps.2021.06.001_bib0028","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.bmcl.2005.03.046","article-title":"Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002)","volume":"15","author":"Ali","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ajps.2021.06.001_bib0029","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.cad.0000185182.80227.48","article-title":"In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate","volume":"17","author":"Chen","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ajps.2021.06.001_bib0030","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1021\/cr5002035","article-title":"Synthesis of nucleoside phosphate and phosphonate prodrugs","volume":"114","author":"Pradere","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0031","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1021\/jm070269u","article-title":"Synthesis and biological activity of a gemcitabine phosphoramidate prodrug","volume":"50","author":"Wu","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.ajps.2021.06.001_bib0032","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.ajps.2021.06.001_bib0033","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/jco.2015.33.15_suppl.2547","article-title":"A first in human Phase I\/II study of NUC-1031 in patients with advanced gynecological cancers","volume":"33","author":"Blagden","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajps.2021.06.001_bib0034","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/jco.2015.33.15_suppl.2514","article-title":"Final results of ProGem1, the first in-human phase I\/II study of NUC-1031 in patients with solid malignancies","volume":"33","author":"Blagden","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajps.2021.06.001_bib0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/cbdd.12845","article-title":"Gemcitabine-(5\u2032-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)","volume":"89","author":"Coyne","year":"2017","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.ajps.2021.06.001_bib0036","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1039\/C4MD00150H","article-title":"A versatile acid-labile linker for antibody\u2013drug conjugates","volume":"5","author":"Finniss","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.ajps.2021.06.001_bib0037","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1021\/ja401350x","article-title":"Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug","volume":"135","author":"Maiti","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ajps.2021.06.001_bib0038","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.1039\/C7CC04872F","article-title":"A cascade enzymatic reaction activatable gemcitabine prodrug with an AIE-based intracellular light-up apoptotic probe for in situ self-therapeutic monitoring","volume":"53","author":"Han","year":"2017","journal-title":"Chem Commun"},{"key":"10.1016\/j.ajps.2021.06.001_bib0039","doi-asserted-by":"crossref","first-page":"17435","DOI":"10.1039\/C5CC06654A","article-title":"The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells","volume":"51","author":"Han","year":"2015","journal-title":"Chem Commun"},{"key":"10.1016\/j.ajps.2021.06.001_bib0040","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1021\/ar3003464","article-title":"Bioprobes based on AIE fluorogens","volume":"46","author":"Ding","year":"2013","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.ajps.2021.06.001_bib0041","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1002\/smll.201600950","article-title":"Intracellular dual fluorescent lightup bioprobes for image-guided photodynamic cancer therapy","volume":"12","author":"Han","year":"2016","journal-title":"Small"},{"key":"10.1016\/j.ajps.2021.06.001_bib0042","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.progpolymsci.2011.08.002","article-title":"Luminogenic polymers with aggregation-induced emission characteristics","volume":"37","author":"Qin","year":"2012","journal-title":"Prog Polym Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0043","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1039\/C8TB00674A","article-title":"Advances in luminescent materials with aggregation-induced emission (AIE) properties for biomedical applications","volume":"6","author":"Wang","year":"2018","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.ajps.2021.06.001_bib0044","doi-asserted-by":"crossref","first-page":"15966","DOI":"10.1021\/jacs.0c06872","article-title":"Substitution activated precise phototheranostics through supramolecular assembly of AIEgen and calixarene","volume":"142","author":"Feng","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ajps.2021.06.001_bib0045","doi-asserted-by":"crossref","first-page":"10754","DOI":"10.1039\/D0TB02272A","article-title":"White light-triggered zwitterionic polymer nanoparticles based on an AIE-active photosensitizer for photodynamic antimicrobial therapy","volume":"8","author":"Ren","year":"2020","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.ajps.2021.06.001_bib0046","doi-asserted-by":"crossref","first-page":"21185","DOI":"10.1021\/acsami.6b06071","article-title":"Zwitterionic phosphorylcholine\u2013TPE conjugate for pH-responsive drug delivery and AIE active imaging","volume":"8","author":"Chen","year":"2016","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.ajps.2021.06.001_bib0047","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jconrel.2020.06.001","article-title":"Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency","volume":"324","author":"Chen","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0048","first-page":"954","article-title":"Rational design of cancer nanomedicine for simultaneous stealth surface and enhanced cellular uptake","volume":"13","author":"Jin","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2021.06.001_bib0049","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1021\/acsnano.0c08185","article-title":"CC chemokine receptor 2-targeting copper nanoparticles for positron emission tomography-guided delivery of gemcitabine for pancreatic ductal adenocarcinoma","volume":"15","author":"Zhang","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2021.06.001_bib0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/003693307802300103","article-title":"Liposomes and vesicles","volume":"23","author":"McDougall","year":"1978","journal-title":"Scott Med J"},{"key":"10.1016\/j.ajps.2021.06.001_bib0051","first-page":"220","article-title":"Research and development of drug delivery systems based on drug transporter and nano-formulation","volume":"15","author":"Peng","year":"2020","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0052","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.1021\/acs.chemrev.5b00046","article-title":"New developments in liposomal drug delivery","volume":"115","author":"Pattni","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0053","doi-asserted-by":"crossref","first-page":"12599","DOI":"10.1021\/acsnano.9b03848","article-title":"Extravasating neutrophils open vascular barrier and improve liposomes delivery to tumors","volume":"13","author":"Naumenko","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2021.06.001_bib0054","first-page":"385","article-title":"Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than Doxil\u24c7","volume":"15","author":"Zhang","year":"2020","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0055","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jconrel.2020.09.055","article-title":"Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment","volume":"329","author":"Sonju","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0056","first-page":"5423","article-title":"Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives","volume":"7","author":"Federico","year":"2012","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.ajps.2021.06.001_bib0057","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jconrel.2019.07.014","article-title":"Tumor-specific delivery of gemcitabine with activatable liposomes","volume":"309","author":"Tucci","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0058","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biomaterials.2018.08.052","article-title":"Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment","volume":"183","author":"Kim","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.ajps.2021.06.001_bib0059","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jconrel.2004.09.001","article-title":"Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs","volume":"100","author":"Immordino","year":"2004","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0060","first-page":"195","article-title":"Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs","volume":"27","author":"Brusa","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ajps.2021.06.001_bib0061","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s13402-013-0146-4","article-title":"PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic","volume":"36","author":"Papa","year":"2013","journal-title":"Cell Oncol"},{"key":"10.1016\/j.ajps.2021.06.001_bib0062","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jconrel.2015.01.026","article-title":"Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer","volume":"201","author":"Poon","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0063","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jconrel.2010.02.021","article-title":"Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity","volume":"144","author":"Paolino","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0064","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2013the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0065","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1166\/jnn.2008.065","article-title":"Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes","volume":"8","author":"Celia","year":"2008","journal-title":"J Nanosci Nanotechnol"},{"key":"10.1016\/j.ajps.2021.06.001_bib0066","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrgastro.2012.115","article-title":"The role of stroma in pancreatic cancer: diagnostic and therapeutic implications","volume":"9","author":"Erkan","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajps.2021.06.001_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2019.100800","article-title":"Engineered nanomedicines with enhanced tumor penetration","volume":"29","author":"Ding","year":"2019","journal-title":"Nano Today"},{"key":"10.1016\/j.ajps.2021.06.001_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119999","article-title":"Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment","volume":"246","author":"Chen","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.ajps.2021.06.001_bib0069","doi-asserted-by":"crossref","first-page":"8668","DOI":"10.1021\/acsnano.7b01026","article-title":"Designing liposomes to suppress extracellular matrix expression to enhance drug penetration and pancreatic tumor therapy","volume":"11","author":"Ji","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2021.06.001_bib0070","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.bbamem.2013.01.020","article-title":"Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity","volume":"1828","author":"Dalla","year":"2013","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.ajps.2021.06.001_bib0071","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00666210","article-title":"Targeting the EGF receptor in breast cancer treatment","volume":"32","author":"LeMaistre","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajps.2021.06.001_bib0072","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2011.08.015","article-title":"EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity","volume":"157","author":"Sandoval","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0073","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.addr.2015.11.011","article-title":"Hyaluronic acid for anticancer drug and nucleic acid delivery","volume":"97","author":"Dosio","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0074","first-page":"521","article-title":"Exploring the relationship of hyaluronic acid molecular weight and active targeting efficiency for designing hyaluronic acid-modified nanoparticles","volume":"14","author":"Zhong","year":"2019","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/acssuschemeng.0c07514","article-title":"Triggered release from cellulose microparticles inspired by wood degradation by fungi","volume":"9","author":"Qu","year":"2021","journal-title":"ACS Sustain Chem Eng"},{"key":"10.1016\/j.ajps.2021.06.001_bib0076","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201802342","article-title":"Gas-shearing fabrication of multicompartmental microspheres: a one-step and oil-free approach","volume":"6","author":"Tang","year":"2019","journal-title":"Adv Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0077","doi-asserted-by":"crossref","first-page":"20058","DOI":"10.1021\/jacs.0c09399","article-title":"Crescent-shaped supramolecular tetrapeptide nanostructures","volume":"142","author":"Wang","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ajps.2021.06.001_bib0078","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jobab.2020.04.003","article-title":"Nanocomposite egg shell powder with in situ generated silver nanoparticles using inherent collagen as reducing agent","volume":"5","author":"Yorseng","year":"2020","journal-title":"J Bioresour Bioproduct"},{"key":"10.1016\/j.ajps.2021.06.001_bib0079","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1039\/C9TB02289A","article-title":"Dendrimer nanoparticles for colorectal cancer applications","volume":"8","author":"Carvalho","year":"2020","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.ajps.2021.06.001_bib0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.progpolymsci.2013.07.005","article-title":"Dendrimer as nanocarrier for drug delivery","volume":"39","author":"Kesharwani","year":"2014","journal-title":"Prog Polym Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0081","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.actbio.2017.02.047","article-title":"Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy","volume":"55","author":"Zhang","year":"2017","journal-title":"Acta Biomater"},{"key":"10.1016\/j.ajps.2021.06.001_bib0082","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejpb.2012.04.007","article-title":"Chitosan-based drug delivery systems","volume":"81","author":"Bernkop-Schn\u00fcrch","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ajps.2021.06.001_bib0083","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1021\/bm101044h","article-title":"Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system","volume":"12","author":"Arias","year":"2011","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ajps.2021.06.001_bib0084","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1039\/C5CS00158G","article-title":"Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy","volume":"45","author":"Liu","year":"2016","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0085","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1021\/acs.jmedchem.8b00293","article-title":"Striking a balance between carbonate\/carbamate linkage bond- and reduction-sensitive disulfide bond-bearing linker for tailored controlled release: in situ covalent-albumin-binding femcitabine prodrugs promote bioavailability and tumor accumulation","volume":"61","author":"Zhang","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.ajps.2021.06.001_bib0086","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jcis.2017.07.047","article-title":"Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment","volume":"507","author":"Han","year":"2017","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0087","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1039\/D0TB00874E","article-title":"Development of mucoadhesive cationic polypeptide micelles for sustained cabozantinib release and inhibition of corneal neovascularization","volume":"8","author":"Han","year":"2020","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.ajps.2021.06.001_bib0088","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1021\/acs.chemrev.8b00199","article-title":"Block copolymer micelles in nanomedicine applications","volume":"118","author":"Cabral","year":"2018","journal-title":"Chem Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0089","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2021.02.016","article-title":"Polymeric micelles in cancer therapy: state of the art","volume":"332","author":"Ghosh","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0090","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/bc2005945","article-title":"Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity","volume":"23","author":"Zhu","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ajps.2021.06.001_bib0091","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/j.biomaterials.2012.11.053","article-title":"The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression","volume":"34","author":"Zhu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ajps.2021.06.001_bib0092","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1021\/acs.nanolett.9b00374","article-title":"Codelivery nanosystem targeting the deep microenvironment of pancreatic cancer","volume":"19","author":"Chen","year":"2019","journal-title":"Nano Lett"},{"key":"10.1016\/j.ajps.2021.06.001_bib0093","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.colsurfb.2016.07.027","article-title":"Antitumor gemcitabine conjugated micelles from amphiphilic comb-like random copolymers","volume":"146","author":"Wang","year":"2016","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.ajps.2021.06.001_bib0094","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acsmacrolett.7b00160","article-title":"Development of a gemcitabine-polymer conjugate with prolonged cytotoxicity against a pancreatic cancer cell line","volume":"6","author":"Joubert","year":"2017","journal-title":"ACS Macro Lett"},{"key":"10.1016\/j.ajps.2021.06.001_bib0095","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1021\/bc400032x","article-title":"Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma","volume":"24","author":"Chitkara","year":"2013","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ajps.2021.06.001_bib0096","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1039\/C5NR06734K","article-title":"Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy","volume":"8","author":"Han","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.ajps.2021.06.001_bib0097","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.colsurfb.2019.05.038","article-title":"One-step preparation of reduction-responsive cross-linked gemcitabine prodrug micelles for intracellular drug delivery","volume":"181","author":"Chen","year":"2019","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.ajps.2021.06.001_bib0098","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1039\/C7PY00443E","article-title":"Polyamino acid-based gemcitabine nanocarriers for targeted intracellular drug delivery","volume":"8","author":"Teng","year":"2017","journal-title":"Polym Chem"},{"key":"10.1016\/j.ajps.2021.06.001_bib0099","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cocis.2010.10.003","article-title":"Mixed micelles self-assembled from block copolymers for drug delivery","volume":"16","author":"Ebrahim Attia","year":"2011","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0100","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1021\/mp4005904","article-title":"Enhanced tumor delivery of gemcitabine via PEG-DSPE\/TPGS mixed micelles","volume":"11","author":"Wang","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ajps.2021.06.001_bib0101","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1021\/acs.biomac.5b01419","article-title":"EGFR-targeted polymeric mixed micelles carrying gemcitabine for treating pancreatic cancer","volume":"17","author":"Mondal","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ajps.2021.06.001_bib0102","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.addr.2009.11.001","article-title":"Targeted delivery using inorganic nanosystem preface","volume":"62","author":"Mukherjee","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0103","doi-asserted-by":"crossref","first-page":"9158","DOI":"10.1021\/jacs.0c03672","article-title":"Molecular-level control over plasmonic properties in silver nanoparticle\/self-assembling peptide hybrids","volume":"142","author":"Wang","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ajps.2021.06.001_bib0104","doi-asserted-by":"crossref","first-page":"235","DOI":"10.7150\/thno.4156","article-title":"Nano-carbons as theranostics","volume":"2","author":"Liu","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.ajps.2021.06.001_bib0105","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1021\/acsnano.0c02114","article-title":"Photonic carbon dots as an emerging nanoagent for biomedical and healthcare applications","volume":"14","author":"Chung","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2021.06.001_bib0106","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.cclet.2020.05.011","article-title":"Recent advancements in graphene adsorbents for wastewater treatment: current status and challenges","volume":"31","author":"Faysal Hossain","year":"2020","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.ajps.2021.06.001_bib0107","article-title":"Use of graphene-based materials as carriers of bioactive agents","author":"Lai","year":"2020","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0108","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1039\/b908012k","article-title":"Hydrophilic multi-walled carbon nanotubes decorated with magnetite nanoparticles as lymphatic targeted drug delivery vehicles","author":"Yang","year":"2009","journal-title":"Chem Commun"},{"key":"10.1016\/j.ajps.2021.06.001_bib0109","doi-asserted-by":"crossref","first-page":"14886","DOI":"10.1002\/chem.201501993","article-title":"Controlled chemical derivatisation of carbon nanotubes with imaging, targeting, and therapeutic capabilities","volume":"21","author":"M\u00e9nard-Moyon","year":"2015","journal-title":"Chemistry"},{"key":"10.1016\/j.ajps.2021.06.001_bib0110","article-title":"Preparation of carbon quantum dots- quinic acid for drug delivery of gemcitabine to breast cancer cells","volume":"61","author":"Samimi","year":"2021","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.ajps.2021.06.001_bib0111","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1039\/C6PY01188H","article-title":"pH-Triggered release of gemcitabine from polymer coated nanodiamonds fabricated by RAFT polymerization and copper free click chemistry","volume":"7","author":"Lai","year":"2016","journal-title":"Polym Chem"},{"key":"10.1016\/j.ajps.2021.06.001_bib0112","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.pnsc.2020.10.011","article-title":"Polymer coated nanodiamonds as gemcitabine prodrug with enzymatic sensitivity for pancreatic cancer treatment","volume":"30","author":"Ye","year":"2020","journal-title":"Prog Nat Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0113","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1002\/cmdc.201800575","article-title":"Designing two-dimensional nanosheets for improving drug delivery to fucose-receptor-overexpressing cancer cells","volume":"13","author":"Gupta","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ajps.2021.06.001_bib0114","doi-asserted-by":"crossref","first-page":"10309","DOI":"10.1021\/acsami.6b16505","article-title":"Progress in nanotheranostics based on mesoporous silica nanomaterial platforms","volume":"9","author":"Singh","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.ajps.2021.06.001_bib0115","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jconrel.2020.07.021","article-title":"Silica nanoparticles: a promising platform for enhanced oral delivery of macromolecules","volume":"326","author":"Abeer","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0116","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/nn800072t","article-title":"Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery","volume":"2","author":"Liong","year":"2008","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2021.06.001_bib0117","first-page":"405","article-title":"Amino functionalized chiral mesoporous silica nanoparticles for improved loading and release of poorly water-soluble drug","volume":"14","author":"Wang","year":"2019","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.ajps.2021.06.001_bib0118","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/molecules21040522","article-title":"Delivery of gemcitabine prodrugs employing mesoporous silica nanoparticles","volume":"21","author":"Malfanti","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ajps.2021.06.001_bib0119","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1021\/acsnano.5b00510","article-title":"Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice","volume":"9","author":"Meng","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2021.06.001_bib0120","doi-asserted-by":"crossref","first-page":"10048","DOI":"10.1021\/nn404083m","article-title":"Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice","volume":"7","author":"Meng","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2021.06.001_bib0121","doi-asserted-by":"crossref","first-page":"21295","DOI":"10.1021\/acsami.5b05619","article-title":"Voltage\/pH-driven mechanized silica nanoparticles for the multimodal controlled release of drugs","volume":"7","author":"Wang","year":"2015","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.ajps.2021.06.001_bib0122","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","article-title":"Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications","volume":"138","author":"Dadfar","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0123","doi-asserted-by":"crossref","first-page":"14596","DOI":"10.1021\/acsami.6b15853","article-title":"Design and proof of programmed 5-aminolevulinic acid prodrug nanocarriers for targeted photodynamic cancer therapy","volume":"9","author":"Wu","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.ajps.2021.06.001_bib0124","doi-asserted-by":"crossref","first-page":"11669","DOI":"10.1021\/acs.chemrev.5b00049","article-title":"Toward biocompatible semiconductor quantum dots: from biosynthesis and bioconjugation to biomedical application","volume":"115","author":"Zhou","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.ajps.2021.06.001_bib0125","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1021\/nn3043463","article-title":"Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer","volume":"7","author":"Lee","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2021.06.001_bib0126","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1021\/jacs.0c00650","article-title":"Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy","volume":"142","author":"Han","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ajps.2021.06.001_bib0127","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.msec.2018.03.025","article-title":"Gemcitabine-loaded gold nanospheres mediated by albumin for enhanced anti-tumor activity combining with CT imaging","volume":"89","author":"Wang","year":"2018","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"10.1016\/j.ajps.2021.06.001_bib0128","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jconrel.2020.09.014","article-title":"Biofilm microenvironment activated supramolecular nanoparticles for enhanced photodynamic therapy of bacterial keratitis","volume":"327","author":"Han","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2021.06.001_bib0129","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1021\/acsnano.6b05541","article-title":"Dual enzymatic reaction-assisted gemcitabine delivery systems for programmed pancreatic cancer therapy","volume":"11","author":"Han","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2021.06.001_bib0130","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajps.2021.06.001_bib0131","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.7150\/thno.38587","article-title":"Transcytosis - an effective targeting strategy that is complementary to \"EPR effect\" for pancreatic cancer nano drug delivery","volume":"9","author":"Liu","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ajps.2021.06.001_bib0132","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1172\/JCI92284","article-title":"Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer","volume":"127","author":"Liu","year":"2017","journal-title":"J Clin Invest"}],"container-title":["Asian Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087621000520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087621000520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:46:53Z","timestamp":1761724013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1818087621000520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":132,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1818087621000520"],"URL":"https:\/\/doi.org\/10.1016\/j.ajps.2021.06.001","relation":{},"ISSN":["1818-0876"],"issn-type":[{"value":"1818-0876","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajps.2021.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Shenyang Pharmaceutical University. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}